Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKRO Akero Therapeutics	$52.27 +0.4%	$50.63	$21.34 ▼ $58.40	$4.16B	-0.15	1.05 million shs	52,368 shs
COLL Collegium Pharmaceutical	$31.05 -0.5%	$30.14	$23.23 ▼ $42.29	$997.51M	0.64	395,897 shs	20,452 shs
PTCT PTC Therapeutics	$48.26 +1.3%	$48.83	$29.02 ▼ $58.38	$3.83B	0.5	873,674 shs	61,584 shs
RNA Avidity Biosciences	$34.70 +2.8%	$30.98	$21.51 ▼ $56.00	$4.14B	0.91	1.42 million shs	192,412 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKRO Akero Therapeutics	0.00%	+0.99%	-3.91%	+38.25%	+94.62%
COLL Collegium Pharmaceutical	0.00%	-4.06%	+4.59%	+15.94%	-3.58%
PTCT PTC Therapeutics	0.00%	-1.89%	-5.12%	-1.16%	+45.97%
RNA Avidity Biosciences	0.00%	+7.34%	+15.18%	+18.37%	-25.18%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKRO Akero Therapeutics	3.645 of 5 stars	3.5	1.0	4.7	2.7	0.8	0.0
COLL Collegium Pharmaceutical	4.4039 of 5 stars	3.4	2.0	3.0	3.4	0.8	2.5
PTCT PTC Therapeutics	4.3479 of 5 stars	4.3	1.0	4.4	2.2	0.8	1.3
RNA Avidity Biosciences	2.5081 of 5 stars	4.5	0.0	0.0	3.5	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKRO Akero Therapeutics	3.00	Buy	$82.50	57.85% Upside
COLL Collegium Pharmaceutical	2.75	Moderate Buy	$43.75	40.92% Upside
PTCT PTC Therapeutics	2.67	Moderate Buy	$65.00	34.70% Upside
RNA Avidity Biosciences	3.06	Buy	$66.35	91.22% Upside

Current Analyst Ratings Breakdown

Latest COLL, AKRO, RNA, and PTCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	RNA Avidity Biosciences	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$70.00
7/10/2025	RNA Avidity Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$55.00
6/27/2025	RNA Avidity Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$96.00
6/24/2025	RNA Avidity Biosciences	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$50.00
6/17/2025	PTCT PTC Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
6/17/2025	RNA Avidity Biosciences	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$55.00
6/11/2025	RNA Avidity Biosciences	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy	$65.00
6/10/2025	RNA Avidity Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$70.00 ➝ $75.00
6/10/2025	RNA Avidity Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$57.00 ➝ $59.00
6/10/2025	RNA Avidity Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$57.00 ➝ $59.00
6/9/2025	RNA Avidity Biosciences	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$48.00 ➝ $54.00

(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$10.75 per share	N/A
COLL Collegium Pharmaceutical	$631.45M	1.58	$12.27 per share	2.53	$7.10 per share	4.37
PTCT PTC Therapeutics	$806.78M	4.74	N/A	N/A	($14.24) per share	-3.39
RNA Avidity Biosciences	$8.93M	468.47	N/A	N/A	$11.94 per share	2.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKRO Akero Therapeutics	-$252.06M	-$1.95	N/A	N/A	N/A	N/A	-15.19%	-13.97%	8/8/2025 (Estimated)
COLL Collegium Pharmaceutical	$69.19M	$1.22	25.45	5.16	N/A	6.61%	99.08%	15.14%	8/6/2025 (Estimated)
PTCT PTC Therapeutics	-$363.30M	$6.51	7.42	N/A	N/A	33.56%	-78.56%	32.11%	8/6/2025 (Estimated)
RNA Avidity Biosciences	-$322.30M	-$3.00	N/A	N/A	N/A	-4,136.00%	-26.96%	-24.57%	8/8/2025 (Estimated)

Latest COLL, AKRO, RNA, and PTCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	COLL Collegium Pharmaceutical	$1.88	N/A	N/A	N/A	$182.26 million	N/A
8/14/2025	Q2 2025	PTCT PTC Therapeutics	-$1.07	N/A	N/A	N/A	N/A	N/A
8/8/2025	Q2 2025	AKRO Akero Therapeutics	-$0.95	N/A	N/A	N/A	N/A	N/A
8/8/2025	Q2 2025	RNA Avidity Biosciences	-$0.93	N/A	N/A	N/A	$1.61 million	N/A
5/12/2025	Q1 2025	AKRO Akero Therapeutics	-$1.01	$0.90	+$1.91	$0.90	N/A	N/A
5/8/2025	Q1 2025	COLL Collegium Pharmaceutical	$1.50	$1.49	-$0.01	$0.07	$174.96 million	$177.76 million
5/8/2025	Q1 2025	RNA Avidity Biosciences	-$0.88	-$0.90	-$0.02	-$0.90	$2.63 million	$1.60 million
5/6/2025	Q1 2025	PTCT PTC Therapeutics	$0.85	$10.04	+$9.19	N/A	$437.16 million	$1.18 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
COLL Collegium Pharmaceutical	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKRO Akero Therapeutics	0.03	16.80	16.80
COLL Collegium Pharmaceutical	3.30	1.08	1.01
PTCT PTC Therapeutics	N/A	3.89	3.85
RNA Avidity Biosciences	N/A	16.91	16.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKRO Akero Therapeutics	N/A
COLL Collegium Pharmaceutical	N/A
PTCT PTC Therapeutics	N/A
RNA Avidity Biosciences	N/A

Insider Ownership

Company	Insider Ownership
AKRO Akero Therapeutics	7.07%
COLL Collegium Pharmaceutical	2.51%
PTCT PTC Therapeutics	5.50%
RNA Avidity Biosciences	3.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKRO Akero Therapeutics	30	79.72 million	74.08 million	Optionable
COLL Collegium Pharmaceutical	210	32.13 million	31.33 million	Optionable
PTCT PTC Therapeutics	1,410	79.26 million	74.90 million	Optionable
RNA Avidity Biosciences	190	120.52 million	115.90 million	Optionable

COLL, AKRO, RNA, and PTCT Headlines

Recent News About These Companies

Avidity Biosciences, Inc. (NASDAQ:RNA) Given Consensus Rating of "Buy" by Analysts

5 hours ago | marketbeat.com

New York State Common Retirement Fund Purchases 87,468 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)

July 20 at 3:53 AM | marketbeat.com

Avidity Biosciences: Three Accelerated Approval Shots Feels Excessive

July 14, 2025 | seekingalpha.com

Avidity Biosciences (NASDAQ:RNA) Shares Gap Up - Here's Why

July 14, 2025 | marketbeat.com

Avidity Biosciences price target raised to $70 from $60 at Evercore ISI

July 12, 2025 | msn.com

Alps Advisors Inc. Has $2.58 Million Position in Avidity Biosciences, Inc. (NASDAQ:RNA)

July 12, 2025 | marketbeat.com

The Goldman Sachs Group Upgrades Avidity Biosciences (NASDAQ:RNA) to Buy

July 12, 2025 | americanbankingnews.com

Avidity Biosciences, Inc. (RNA) Balance Sheet - Yahoo Finance

July 11, 2025 | finance.yahoo.com

Avidity Biosciences (NASDAQ:RNA) Coverage Initiated by Analysts at The Goldman Sachs Group

July 10, 2025 | marketbeat.com

Mirae Asset Global Investments Co. Ltd. Boosts Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)

July 6, 2025 | marketbeat.com

Avidity Biosciences, Inc. (RNA) - Yahoo Finance

July 3, 2025 | finance.yahoo.com

7RNA : Expert Outlook: Avidity Biosciences Through The Eyes...

June 27, 2025 | benzinga.com

Avidity Biosciences (NASDAQ:RNA) Receives "Overweight" Rating from Cantor Fitzgerald

June 27, 2025 | marketbeat.com

Avidity Biosciences’ SWOT analysis: innovative RNA therapies stock faces pivotal year

June 26, 2025 | investing.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Rating of "Buy" from Analysts

June 26, 2025 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Earns Outperform Rating from Analysts at Sanford C. Bernstein

June 24, 2025 | marketbeat.com

Avidity, Dyne get Bernstein ratings as oligonucleotide muscle trials advance

June 24, 2025 | investing.com

SG Americas Securities LLC Takes $516,000 Position in Avidity Biosciences, Inc. (NASDAQ:RNA)

June 23, 2025 | marketbeat.com

Avidity Biosciences’ SWOT analysis: innovative RNA firm eyes 3-drug launch by 2027

June 20, 2025 | investing.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells $27,548.64 in Stock

June 19, 2025 | insidertrades.com

Avidity Biosciences’ SWOT analysis: innovative RNA tech targets rare disease stock potential

June 16, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
BigBear.ai: Why a 90% Rally Could Be Just the Start
By Jeffrey Neal Johnson | July 10, 2025
View BigBear.ai: Why a 90% Rally Could Be Just the Start
3 Catalysts Driving Plug Power’s Turnaround Case
By Jeffrey Neal Johnson | July 18, 2025
View 3 Catalysts Driving Plug Power’s Turnaround Case
Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
By Chris Markoch | July 6, 2025
View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
D-Wave Goes International With South Korea Partnership
By Nathan Reiff | June 23, 2025
View D-Wave Goes International With South Korea Partnership

COLL, AKRO, RNA, and PTCT Company Descriptions

Akero Therapeutics NASDAQ:AKRO

$52.26 +0.19 (+0.36%)

As of 10:17 AM Eastern

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Collegium Pharmaceutical NASDAQ:COLL

$31.04 -0.16 (-0.50%)

As of 10:16 AM Eastern

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

PTC Therapeutics NASDAQ:PTCT

$48.26 +0.63 (+1.31%)

As of 10:17 AM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Avidity Biosciences NASDAQ:RNA

$34.70 +0.94 (+2.78%)

As of 10:16 AM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time